Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson’s Disease
- 121 Downloads
An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including those of the EU (under the Mutual Recognition Procedure), it is approved for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. In several other countries, including the USA, it is approved for the treatment of motor fluctuations in patients with advanced PD. In adults with advanced PD, levodopa/carbidopa ES improved motor fluctuations, activities of daily living and health-related quality of life (HR-QOL) during short-term (12-week) treatment, with the beneficial effects on motor fluctuations largely sustained over the longer term (up to 7 years). Levodopa/carbidopa ES was generally well tolerated in this patient population, with adverse events (AEs) associated with aging, advanced PD-related comorbidities, the procedure/device or dopaminergic therapy. Its safety profile was comparable to that of oral levodopa/carbidopa with respect to non-procedure/device-associated AEs; most procedure/device-associated AEs were consistent in nature and incidence with medically recognised complications of the procedure in non-PD patients. Current evidence indicates that levodopa/carbidopa ES is an effective and generally well tolerated option for the treatment of motor fluctuations in patients with levodopa-responsive advanced PD who are not being effectively managed with non-invasive therapies.
During the peer review process, the manufacturer of levodopa/carbidopa enteral suspension was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
- 10.AbbVie Ltd. Duodopa 20 mg/mL + 5 mg/mL intestinal gel: UK summary of product characteristics. 2017. http://www.medicines.org.uk/emc/. Accessed 12 Dec 2018.
- 12.Murata M, Mihara M, Hasegawa K, et al. Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease. Ther Adv Neurol Disord. 2018. https://doi.org/10.1177/1756286418759315.PubMedPubMedCentralCrossRefGoogle Scholar
- 20.Palhagen SE, Sydow O, Johansson A, et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord. 2016;29:17–23.PubMedCrossRefGoogle Scholar
- 25.European Medicines Agency. Public summary of position opinion for orphan designation of levodopa/carbidopa (gastroenteral use). 2016. http://www.ema.europa.eu/en. Accessed 22 Mar 2019.
- 26.AbbVie Inc. DUOPA (carbidopa and levodopa) enteral suspension: US prescribing information. 2018. http://www.rxabbvie.com/. Accessed 12 Dec 2018.
- 32.Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133–44.PubMedCrossRefGoogle Scholar
- 34.National Institute for Health and Care Excellence. Parkinson’s disease in adults. 2017. https://www.nice.org.uk/. Accessed 19 Jun 2019.
- 46.Othman AA, Chatamra K, Mohamed ME, et al. Jejunal infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in Japanese subjects with advanced Parkinson’s disease: pharmacokinetics and pilot efficacy and safety. Clin Pharmacokinet. 2015;54(9):975–84.PubMedPubMedCentralCrossRefGoogle Scholar